

# Health technology assessment on C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care settings

## For public consultation

### Consultation Feedback Form

Your feedback is very important to us. We welcome responses to all questions as well as any additional comments you would like to make.

When commenting on a specific section of a document, it would help if you can identify which element you are commenting on and the relevant page number.

**The closing date for consultation is 5pm on Friday, 15 March 2019.**

You may email or post a completed form to us. You may also complete and submit your feedback online at [www.hiqa.ie](http://www.hiqa.ie).

### About you

<b>Name</b>	
<b>Address</b>	
<b>Contact details</b>	
<b>Date</b>	

## General Information and Questions

You may provide us with feedback on the specific questions (see questions that follow), or alternatively you may provide us with general comments.

### Part 1

Are you replying in a personal capacity or on behalf of an institution or organisation?

Personal capacity

On behalf of an institution

On behalf of an organisation

### Part 2

Please outline any general or specific feedback on the documents. In your response, where applicable, please specify the section to which you are referring.

#### Question 1

The report contains scientific evidence regarding the epidemiology of acute respiratory tract infections, clinical effectiveness, safety and cost-effectiveness of C-reactive protein point-of-care testing. Do you have any suggested alterations or additions to the scientific evidence included in the report?

*Please comment*

## Question 2

The report includes contextual information that supports our understanding of the applicability of the scientific evidence to the Irish setting, and the organisational challenges that might arise. Do you have any suggested alterations or additions to the contextual information included in the report?

*Please comment*

## Question 3


The combination of the scientific evidence and contextual information underpins our interpretation of the data. Do you have any suggested alterations or additions to the interpretation of the evidence included in the report?

*Please comment*

**Question 4**

If you had any issues with the clarity or presentation of the report, can you identify the sections that caused difficulties?


*Please comment*



**Question 5**

Do you have any general comments you would like to make about this document?

*Please comment*



# Thank you for taking the time to give us your views.

After the closing date, we will assess all feedback and use it to finalise our documents. The final documents and the Statement of Outcomes (a summary of the responses) will be published on <http://www.hiqa.ie>.

If you wish to do so, you can request that your name and/or organisation be kept confidential and excluded from the published summary of responses. Please note that we may use your details to contact you about your responses. We do not intend to send responses to each individual respondent.

Please return your form to us either by email or post:



[consultation@hiqa.ie](mailto:consultation@hiqa.ie)



Health Information and Quality Authority  
HTA on C-reactive protein point-of-care testing to guide antibiotic prescribing  
for acute respiratory tract infections in primary care settings  
George's Court  
George's Lane  
Dublin 7



If you have any questions you can contact the consultation team by calling (01) 814 7463.

**Please return your form to us either by email or post before  
5pm on Friday, 15 March 2019.**

Please note that the Authority is subject to the Freedom of Information Acts and the statutory Code of Practice regarding FOI.

For that reason, it would be helpful if you could explain to us if you regard the information you have provided as confidential. If we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances.